About Serca Pharmaceuticals

Serca Pharmaceuticals is a biopharmaceutical company focusing on development of its lead drug candidate intended for use in a novel treatment of acute myocardial infarction. 

Serca Pharmaceuticals (Oslo, Norway) was established in 2018 based on more than 10 years of research at University of Oslo/Oslo University Hospital (OUH) on the signal pathways regulating heart contractility. 

Serca Pharmaceuticals’ lead candidate 13-M is a small molecule with the potential to reduce myocardial infarction area in the treatment of acute myocardial infarction by normalizing the cardiac cell calcium (Ca2+) transport via the SERCA2 pump. 

The Company initiated collaboration with Cadila Pharmaceuticals (India) for the nonclinical product development and the subsequent clinical Phase 1 and Phase 2 trials. The Company’s strategy is to demonstrate clinical Proof of Concept in Phase 2 followed by further worldwide development and commercialization. The Company will seek to grow organically and through partnering and collaboration with major players in the Field.

Skjermbilde 2021 04 26 kl. 09.03.32